// App-Quantinova.ai

7017 : A registry-based, observational safety study of inotuzumab ozogamicin (InO) treatment in patients (pts) with B-cell precursor acute lymphoblastic leukemia (ALL) who proceeded to hematopoietic stem cell transplant (HSCT).

Researchers

Presenter

  • Marcos J.G. De Lima

Principal Investigators

  • Partow Kebriaei

  • Francesco Lanza

  • Christina Cho

  • Sergio Giralt

  • Gizelle Popradi

  • Michael T Hemmer

  • Xin Zhang

  • Richa Shah

  • Verna L. Welch

  • Erik Vandendries

  • Matthias Stelljes

  • David I. Marks

  • Wael Saber

Medical Centers

  • University Hospitals Cleveland Medical Center, Cleveland, OH, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Ospedale di Ravenna, Ravenna, Italy

  • Memorial Sloan Kettering Cancer Center, New York, NY, McGill University Health Centre, Montréal, QC, Canada

  • Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee, WI

  • Pfizer Inc., New York, NY, Pfizer Inc., Cambridge, MA

  • Universitatsklinikum Munster, Munster, Germany

  • University of Bristol, Bristol, United Kingdom

Locations

  • Italy

  • Canada

  • China

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Inotuzumab ozogamicin

Outcome

  • N/A

Study Design

  • Observational

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved